Who Paid My Doc
A Phase II, Single-Blind, Randomized, Controlled Study to Evaluate the
Research payments
$4,007,744
Through program year 2025, $4,007,744 in research payments was reported against A Phase II, Single-Blind, Randomized, Controlled Study to Evaluate the, across 810 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $438,597 | 136 |
| 2024 | Research | $1,517,923 | 495 |
| 2023 | Research | $2,051,224 | 179 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Nicola Klein Oakland, CA Named on 50 payments
- Holly Lim West Covina, CA Named on 45 payments
- Daniel Neumann Layton, UT Named on 45 payments
- Julie Shepard Dayton, OH Named on 32 payments
- Adam Hutchinson Layton, UT Named on 29 payments
- Teena Hughes Tampa, FL Named on 27 payments
- Carmen Deseda San Juan, PR Named on 27 payments
- Joseph Domachowske Syracuse, NY Named on 25 payments
- Jibran Atwi Lake Charles, LA Named on 24 payments
- Colton Ragsdale Layton, UT Named on 23 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.